Neurocrine Biosciences Inc NBIX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $115.93
- Day Range
- $114.95–116.41
- 52-Week Range
- $103.63–157.98
- Bid/Ask
- $110.75 / $115.08
- Market Cap
- $11.62 Bil
- Volume/Avg
- 936,435 / 913,769
Key Statistics
- Price/Earnings (Normalized)
- 19.47
- Price/Sales
- 5.58
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 1,500
- Website
- https://www.neurocrine.com
Competitors
Valuation
|
Metric
|
NBIX
|
TEVA
|
SNY
|
|---|---|---|---|
Price/Earnings (Normalized) | 19.47 | 6.49 | 12.68 |
Price/Book Value | 4.63 | 3.11 | 1.99 |
Price/Sales | 5.58 | 1.20 | 2.82 |
Price/Cash Flow | 18.02 | 12.37 | 14.59 |
Price/Earnings
NBIX
TEVA
SNY
Financial Strength
|
Metric
|
NBIX
|
TEVA
|
SNY
|
|---|---|---|---|
Quick Ratio | 3.78 | 0.46 | 0.52 |
Current Ratio | 4.19 | 0.89 | 1.00 |
Interest Coverage | 4.18 | 0.83 | 8.61 |
Quick Ratio
NBIX
TEVA
SNY
Profitability
|
Metric
|
NBIX
|
TEVA
|
SNY
|
|---|---|---|---|
Return on Assets (Normalized) | 19.61% | 7.18% | 7.59% |
Return on Equity (Normalized) | 27.66% | 43.52% | 14.17% |
Return on Invested Capital (Normalized) | 28.05% | 13.87% | 10.36% |
Return on Assets
NBIX
TEVA
SNY
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Zoetis Inc Class A
ZTS
| Crhflwbnt | Pzdq | $88.3 Bil | |||
| Merck KGaA ADR
MKKGY
| Jkpkpfyw | Mswtgr | $78.0 Bil | |||
| Haleon PLC ADR
HLN
| Lxsphjcwf | Snlkm | $48.4 Bil | |||
| Viatris Inc
VTRS
| Rfnqrkgb | Gfzk | $13.8 Bil | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Dzxkgksn | Sxfc | $13.5 Bil | |||
| Catalent Inc
CTLT
| Rlggvztsy | Dndsm | $10.9 Bil | |||
| Prestige Consumer Healthcare Inc
PBH
| Wbdkqwll | Ctbcw | $3.5 Bil | |||
| Perrigo Co PLC
PRGO
| Pvygycpz | Qsndb | $3.5 Bil | |||
| Green Thumb Industries Inc
GTBIF
| Qcyskzqp | Jfyq | $2.5 Bil | |||
| Curaleaf Holdings Inc
CURLF
| Gxtybdcb | Nwbf | $2.3 Bil |
United States